Novo Nordisk opens a new research centre in Oxford

| By | Drug Development, Novo Nordisk, R&D

A new centre for research to develop a new generation of medicines that will transform the lives of people living with diabetes opened in Oxford (UK).

Novo Nordisk Research Centre Oxford (NNRCO) is a strategic alliance between Oxford University and Novo Nordisk, building on their longstanding relationship by establishing a landmark collaboration research centre for the advancement of the type 2 diabetes research in Oxford.

The research carried out at NNRCO aims to discover innovative medicines that make a difference to the lives of patients with diabetes. NNRCO will also help to train the next generation of type 2 diabetes research scientists by co-sponsoring students.

Between 2017 and 2021, NNRCO will employ up to 100 researchers who will be visitors to Oxford University in various capacities, including Visiting Professors and Industrial Visiting Fellows. They will be located in new state-of-the-art laboratories in the BioEscalator Building on the Old Road Campus from 2018, but are currently based at the Centre for Cellular and Molecular Physiology building.

NNRCO research departments:

  • Discovery Bioinformatics – aims to go beyond data analysis services to direct and drive target discovery in type 2 diabetes using multiple bioinformatics approaches.
  • Advanced Genomics – aims to discover and validate modifiers of nutrient flux, with a focus on the relationship between fatty liver disease and insulin resistance, using cellular genomics methods such as single-cell sequencing and CRISPR.
  • Stem Cell Engineering – aims to discover novel secreted factors and corresponding signalling pathways which modify beta-cell function, health and viability, by combining in vitro-differentiated human stem cell-derived models with CRISPR and other genomic targeting techniques to assay beta-cell function from a single gene up to a genome-wide scale.
  • High-Throughput Imaging – seeks to identify novel secreted proteins and peptides that modulate pancreatic beta-cell function and survival using robotic live-cell microscopy and other high-throughput cell physiology approaches.

Professor Mads Krogsgaard Thomsen, CSO and EVP at Novo Nordisk, commented:

“I am very excited to see the strategic alliance between Novo Nordisk and the University of Oxford flourish and set the bar for international collaborative cutting edge scientific research to spearhead collaboration on new treatment for people with type 2 diabetes and other serious chronic diseases.”

SOURCE: novo nordisk
GMP news
Pharmaceutical industry News and events. Technology transfer and contract manufacturing of medicines.